Review



circulating tumor dna assay guardantomni next-generation sequencing panel  (Guardant Health)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 90

    Structured Review

    Guardant Health circulating tumor dna assay guardantomni next-generation sequencing panel
    Circulating Tumor Dna Assay Guardantomni Next Generation Sequencing Panel, supplied by Guardant Health, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/circulating+tumor+dna+assay+guardantomni+next-generation+sequencing+panel/circulating+tumor+dna+assay+guardantomni+next+generation+sequencing+panel/pm38051531-46-14-23
    Average 90 stars, based on 1 article reviews
    circulating tumor dna assay guardantomni next-generation sequencing panel - by Bioz Stars, 2026-09
    90/100 stars

    Images

    Related Articles

    Clinical Proteomics:

    Article Title: Liver Metastases and Immune Checkpoint Inhibitor Efficacy in Patients With Refractory Metastatic Colorectal Cancer
    Article Snippet: .. Plasma tumor mutation burden (pTMB) was determined from blood samples collected prior to study therapy using a circulating tumor DNA assay (GuardantOMNI next-generation sequencing panel; Guardant Health Inc) and reported as mutations per megabase (Mb). ..

    Mutagenesis:

    Article Title: Liver Metastases and Immune Checkpoint Inhibitor Efficacy in Patients With Refractory Metastatic Colorectal Cancer
    Article Snippet: .. Plasma tumor mutation burden (pTMB) was determined from blood samples collected prior to study therapy using a circulating tumor DNA assay (GuardantOMNI next-generation sequencing panel; Guardant Health Inc) and reported as mutations per megabase (Mb). ..

    Next-Generation Sequencing:

    Article Title: Liver Metastases and Immune Checkpoint Inhibitor Efficacy in Patients With Refractory Metastatic Colorectal Cancer
    Article Snippet: .. Plasma tumor mutation burden (pTMB) was determined from blood samples collected prior to study therapy using a circulating tumor DNA assay (GuardantOMNI next-generation sequencing panel; Guardant Health Inc) and reported as mutations per megabase (Mb). ..

    other:

    Article Title: Liver Metastases and Immune Checkpoint Inhibitor Efficacy in Patients With Refractory Metastatic Colorectal Cancer: A Secondary Analysis of a Randomized Clinical Trial.
    Article Snippet: 2023;6(12):e2346094. doi:10.1001/jamanetworkopen.2023.46094 (Reprinted) December 5, 2023 2/11 Downloaded from jamanetwork.com by Jabin Prakash on 03/06/2024 circulating tumor DNA assay (GuardantOMNI next-generation sequencing panel; Guardant Health Inc) and reported as mutations per megabase (Mb).



    Similar Products

    90
    Guardant Health circulating tumor dna assay guardantomni next-generation sequencing panel
    Circulating Tumor Dna Assay Guardantomni Next Generation Sequencing Panel, supplied by Guardant Health, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/circulating+tumor+dna+assay+guardantomni+next-generation+sequencing+panel/circulating+tumor+dna+assay+guardantomni+next+generation+sequencing+panel/pm38051531-46-14-23
    Average 90 stars, based on 1 article reviews
    circulating tumor dna assay guardantomni next-generation sequencing panel - by Bioz Stars, 2026-09
    90/100 stars
      Buy from Supplier

    Image Search Results